<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565981</url>
  </required_header>
  <id_info>
    <org_study_id>FLUSALEM</org_study_id>
    <nct_id>NCT00565981</nct_id>
  </id_info>
  <brief_title>A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response</brief_title>
  <official_title>Subcutaneous MabCampath® (Alemtuzumab) and Oral Fludara® (Fludarabinephosphate) for the Treatment of Refractory or Relapsed Chronic Lymphocytic Leukemia in 2nd or 3rd Line of Treatment: A Pilot Trial (FLUSALEM) for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label multicenter, two-step, non-randomized (pilot) study to analyze the safety of 4
      cycles of 3-day 40mg/m2 oral fludarabine with simultaneous thrice weekly application of 30mg
      alemtuzumab s.c. in patients with B-CLL disease in 1st and 2nd relapse after any primary
      treatment or with disease refractory to any therapy in 1st or 2nd line (including
      Fludarabine, ). This regimen is preceded by an escalation phase with 3-10-30 mg of
      alemtuzumab s.c.

      After the first phase (completed treatment of 7 patients) an interim analysis of safety and
      efficacy will be performed. In case of a sufficient risk benefit assessment followed by the
      enrollment of further 21 patients. Final analysis of safety and preliminary efficacy will be
      based on all patients enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 13, 2008</completion_date>
  <primary_completion_date type="Actual">February 13, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>within the duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete and overall response rate</measure>
    <time_frame>within the duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infections grade III, IV</measure>
    <time_frame>within the duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of CMV reactivation</measure>
    <time_frame>within the duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to retreatment</measure>
    <time_frame>within duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>within duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response in lymphatic compartments</measure>
    <time_frame>within duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular response/ immunologic MRD response</measure>
    <time_frame>within duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>within duration of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Overall study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine phosphate</intervention_name>
    <description>orally, 40 mg/m2 d1-3 q4w, x4 cycles</description>
    <arm_group_label>Overall study</arm_group_label>
    <other_name>Fludara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose</description>
    <arm_group_label>Overall study</arm_group_label>
    <other_name>MabCampath®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with CD23+, CD5+, CD19+, light chain monoclonal B CLL

          -  1st or 2nd relapse after fludarabine or any other primary treatment regimen or
             refractory to primary or secondary treatment (including fludarabine) and
             simultaneously indication for treatment according to the NCI Workshop Criteria 1996

          -  Age 19-75

          -  WHO performance score 0-2

          -  Informed consent given by the patient

        Exclusion Criteria:

          -  HIV positive or positive for Hepatitis B or C

          -  active uncontrolled infection

          -  child bearing age without adequate control of fertility, pregnant or lactating women

          -  intolerance towards any ingredient of either oral fludarabine or alemtuzumab

          -  allergy against foreign proteins

          -  previous treatment with alemtuzumab

          -  treatment with an experimental drug within the previous 2 months

          -  second malignant disease (non CLL)

          -  CLL in transformation (Richter syndrome)

          -  decreased kidney-function with creatinine-clearance &lt; 30ml/min

          -  severe concomitant diseases or major organ dysfunctions

          -  patients who are unable to comply with the requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IIIrd Medical Department for Hematology, Oncology, Rheumatology, Infectiology and Hemostasiology at the Medical University of Salzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6806</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Fürstenfeld</name>
      <address>
        <city>Fürstenfeld</city>
        <zip>A-8280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck/ Klinik für Innere Medizin</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johanns LK</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Krankenhaus der Landeshauptstadt St. Pölten</name>
      <address>
        <city>St. Poelten</city>
        <zip>A-3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-CLL</keyword>
  <keyword>refractory</keyword>
  <keyword>molecular profiling</keyword>
  <keyword>alemtuzumab</keyword>
  <keyword>fludarabinephosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

